XSpray Pharma AB (ST:XSPRAY) — Stock Price

Skr14.34 SEK
▼ -4.53% today

XSpray Pharma AB (ST:XSPRAY) is currently trading at Skr14.34 SEK, down 4.53% today. Over the past 52 weeks, shares have ranged between Skr14.34 and Skr63.40. This page tracks XSpray Pharma AB's live share price on the ST exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see XSpray Pharma AB (XSPRAY) market capitalisation.

XSpray Pharma AB (XSPRAY) Stock Price Chart — Daily History & Trading Volume

The chart below tracks XSpray Pharma AB's daily closing share price and trading volume on the ST exchange over the past year, giving a clear view of recent price momentum and liquidity.

XSpray Pharma AB Income Statement — Revenue, Profit & Earnings by Year

XSpray Pharma AB's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 20252024202320222021
Total Revenue Skr0.00 Skr0.00 Skr0.00 Skr0.00 Skr0.00
Cost of Revenue Skr5.58 Million Skr8.55 Million Skr9.19 Million Skr9.53 Million Skr8.87 Million
Gross Profit Skr-5.58 Million Skr-8.55 Million Skr-9.19 Million Skr-9.53 Million Skr-8.87 Million
Research & Development Skr10.75 Million Skr81.98 Million Skr33.59 Million Skr22.22 Million Skr38.57 Million
SG&A Skr108.53 Million Skr166.87 Million Skr158.10 Million Skr109.60 Million Skr58.38 Million
Total Operating Expenses Skr156.27 Million Skr287.04 Million Skr181.73 Million Skr131.38 Million Skr96.95 Million
Operating Income Skr-161.85 Million Skr-283.24 Million Skr-181.73 Million Skr-133.07 Million Skr-97.95 Million
EBITDA Skr-156.27 Million Skr-277.76 Million Skr-169.81 Million Skr-122.13 Million Skr-87.82 Million
EBIT Skr-161.85 Million Skr-283.24 Million Skr-179.01 Million Skr-131.66 Million Skr-96.69 Million
Interest Expense Skr16.85 Million Skr1.93 Million Skr675.00K Skr12.00K Skr4.00K
Income Before Tax Skr-171.55 Million Skr-285.67 Million Skr-179.68 Million Skr-131.67 Million Skr-96.70 Million
Income Tax Expense Skr-104.00K Skr-151.00K Skr-17.00K Skr-1.40 Million Skr4.00K
Net Income Skr-171.44 Million Skr-285.52 Million Skr-179.67 Million Skr-130.27 Million Skr-96.70 Million

XSpray Pharma AB Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes XSpray Pharma AB's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 20252024202320222021
Total Assets Skr769.35 Million Skr796.34 Million Skr765.26 Million Skr585.43 Million Skr622.90 Million
Total Current Assets Skr182.90 Million Skr235.07 Million Skr217.81 Million Skr132.23 Million Skr282.06 Million
Cash & Equivalents
Short-term Investments Skr3.02 Million Skr-3.00 Million
Net Receivables Skr3.84 Million Skr6.49 Million Skr4.17 Million Skr2.58 Million Skr2.50 Million
Inventory Skr22.30 Million Skr20.34 Million Skr43.78 Million Skr8.55 Million Skr6.20 Million
Property, Plant & Equipment Skr70.99 Million Skr79.19 Million Skr107.65 Million Skr64.60 Million Skr44.60 Million
Goodwill
Total Liabilities Skr164.70 Million Skr173.25 Million Skr71.85 Million Skr29.41 Million Skr31.15 Million
Total Current Liabilities Skr21.66 Million Skr146.14 Million Skr39.90 Million Skr28.85 Million Skr29.97 Million
Long-term Debt Skr121.32 Million Skr0.00
Net Debt Skr16.36 Million Skr-80.02 Million Skr-129.50 Million Skr-118.04 Million Skr-268.65 Million
Total Stockholder Equity Skr604.65 Million Skr623.10 Million Skr693.41 Million Skr556.02 Million Skr591.75 Million
Retained Earnings Skr-1.01 Billion Skr-840.25 Million Skr-554.73 Million Skr-375.06 Million Skr-243.39 Million

XSpray Pharma AB Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how XSpray Pharma AB generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 20252024202320222021
Operating Cash Flow Skr-193.16 Million Skr-222.37 Million Skr-203.28 Million Skr-110.18 Million Skr-51.61 Million
Capital Expenditures Skr29.19 Million Skr42.14 Million Skr54.10 Million Skr128.29 Million Skr95.96 Million
Free Cash Flow Skr-193.16 Million Skr-264.51 Million Skr-257.38 Million Skr-238.47 Million Skr-147.57 Million
Investing Cash Flow Skr-29.19 Million Skr-42.14 Million Skr-65.88 Million Skr-135.34 Million Skr-105.82 Million
Financing Cash Flow Skr168.29 Million Skr306.11 Million Skr315.59 Million Skr93.81 Million Skr103.71 Million
Dividends Paid Skr2.18 Million Skr2.21 Million
Stock-Based Compensation
Depreciation Skr5.58 Million Skr8.55 Million Skr9.19 Million Skr9.53 Million Skr8.87 Million
Change in Cash Skr-54.49 Million Skr41.93 Million Skr46.14 Million Skr-151.72 Million Skr-53.72 Million

XSpray Pharma AB Earnings History — EPS Actual vs. Analyst Estimates

Track XSpray Pharma AB's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Report Date EPS Actual EPS Estimate Surprise
Feb 12, 2026 -0.89 1.75 -150.86%
Nov 05, 2025 -1.25 -1.65 +24.24%
Aug 15, 2025 -2.35 -1.71 -37.43%
May 07, 2025 -1.14 -1.81 +37.02%
Feb 12, 2025 -2.36 -1.82 -29.67%
Nov 06, 2024 -2.44 -1.39 -75.54%
Aug 07, 2024 -1.64 -1.55 -5.81%
May 08, 2024 -2.17